白蛋白结合型紫杉醇联合替吉奥一线治疗老年晚期胰腺癌患者的临床观察  

Clinical observation of the effects of albumin-bound paclitaxel plus S-1 in treating elderly patients with advanced pancreatic cancer

作　　者：刘甜 熊琦[1] 胡毅[1] 

机构地区：[1]解放军总医院肿瘤内科,北京100853

出　　处：《现代肿瘤医学》2018年第5期722-725,共4页Journal of Modern Oncology

摘　　要：目的:探讨白蛋白结合型紫杉醇联合替吉奥方案一线治疗老年晚期胰腺癌患者的疗效及安全性。方法:回顾性分析2014年10月至2016年10月解放军总医院28例接受白蛋白结合型紫杉醇联合替吉奥方案一线化疗的晚期转移性胰腺癌老年患者(年龄≥60岁)的临床资料。根据NCI-CTC3.0标准每周期评价不良反应,依据实体肿瘤RECIST标准每2周期评估疗效,并随访其生存情况。结果:接受白蛋白结合型紫杉醇联合替吉奥方案一线化疗的28例患者的ORR为42.9%(12/28),DCR为82.1%(23/28)。接受治疗的28例患者的中位PFS为9.4个月(95%CI:6.1~12.7个月),中位OS为12.6个月(95%CI:7.6~17.5个月)。不良反应发生情况:白细胞减少(71.4%)、恶心呕吐(53.6%)、脱发(46.4%)、感觉神经异常(53.6%)。Ⅲ-Ⅳ度不良反应包括白细胞减少(21.4%)、脱发(3.6%)、口腔黏膜炎(3.6%)、感觉神经异常(3.6%)。结论:白蛋白结合型紫杉醇联合替吉奥方案一线治疗老年晚期胰腺癌疗效较好,不良反应可耐受。Objective To discuss the efficacy and safety of albumin - bound paclitaxel plus S - 1 in treating eld-erly patients with advanced pancreatic cancer. Methods ： Clinical information of 28 elderly patients （ age 60） with advanced pancreatic cancer,who have received albumin - bound paclitaxel plus S - 1 as first - line therapy in Chinese PLA General Hospital from October 2014 to October 2016,was retrospectively analyzed. According to NCI - CTC3. 0 criteria,the adverse reactions were evaluated per cycle. The efficacy was evaluated every two cycles based on the solid tumor RECIST criteria,and the survival situation was followed up as well. Results： For the 28 patients who have re-ceived albumin - bound paclitaxel plus S - 1 as first therapy,the objective response rate （ ORR） was 42. 9% （1 2 /28） and the disease control rate （ DCR） was 82. 1% （2 3 /2 8 ） . Among the 28 patients, the median PFS was 9. 4 （95% Cl ：6. 1 -12. 7） months and the median OS was 12. 6 （95% Cl ：7. 6 -17. 5 ） months. The occurrence of ad-verse reactions included leukopenia （71.4% ） , nausea/vomiting （ 53. 6% ） , alopecia （46. 4% ） , sensory neuropathy （53. 6% ）. Grade IH - IV adverse reactions included leukopenia （21.4%） , alopecia （3. 6% ） , oral mucositis （3.6%） , sensory neuropathy （3.6% ）. Conclusion ： Albumin - bound paclitaxel plus S - 1 as first - line therapy in treating elderly patients with advanced pancreatic cancer shows good clinical efficacy, and the adverse reactions are tolerable.

关 键 词：胰腺癌 白蛋白结合型紫杉醇 替吉奥 老年人 

分 类 号：R739.5[医药卫生—肿瘤]